Evaluation of interferon β-1b therapy effects on the level and abnormal nature of immunoglobulin G in patients with multiple sclerosis
DOI:
https://doi.org/10.14739/2310-1210.2018.6.146558Keywords:
multiple sclerosis, interferonβ-1b, immunoglobulin, antibodiesAbstract
Aim: to study and evaluate the interferon β-1b (INF) therapy efficiency on the level and abnormal nature of immunoglobulin G in patients with multiple sclerosis (MS).
Materials and methods. This scientific work was performed at the Neurology Department and the Department of Histology, Cytology and Embryology of theLvivNationalMedicalUniversity named after Danylo Halytsky and in theLvivRegionalResearchCenter for the Study of Multiple Sclerosis and Other Demyelinating Diseases on the basis of theLvivRegionalClinicalHospital. The inclusion criteria for patients were age between 18 and 65 years as well as definite diagnosis of MS according to McDonald Diagnostic Criteria for MS (2010).
32 patients with MS and 23 practically healthy persons were enrolled in the study. After a written informed consent obtaining from the patient there was a peripheral venous blood sampling using a blood-collection tube system Vacuette. Serum samples were prepared for antibodies to myelin basic protein (MBP) determination and identification of immunoglobulin glycosylation by means of lectin-immunoenzymatic assay.
Results. Elevated levels of anti-MBP IgG and IgM in the treatment-naive MS patients were determined in comparison with the healthy persons. At the same time, higher exposure of anti-inflammatory sialic acid residues on IgG molecules and associated native immune complexes were observed in the group of patients who received INF therapy as well as higher exposure of fucosylated tri-mannose residues on measles IgG molecules and associated native immune complexes in comparison with the untreated patients.
Conclusions: The blood serum of MS patients who received INF therapy were characterized by lower levels of IgG and IgM antibodies to MBP and higher exposure of sialic acid terminal residues on IgG and IgM molecules in comparison with the untreated patients. It is reasonable to assume that INF therapy could lead to anti-inflammatory native IgG complexes formation and / or decrease in IgG and IgM autoantibodies against the nervous system components, as it has been shown for autoantibodies to MBP.
References
Voloshyna, N. P., Vasylovskyi, V. V., & Chernenko, M. E. (2013) Vliyanie infekcionnogo faktora na sostoyanie gematoe'ncefalicheskogo bar'era y bol'nukh rasseyannym sklerozom [Infl uence of infectious factor on the condition of bloodbrain barrier in patients with multiple sclerosis]. Ukrainskyi visnyk psykhonevrolohii, 21(1), 5–7. [in Russian].
Negrych, T. I., Kyryliuk, S. Ya., Yevtushenko, S. K., & Khubetova, I. V. (2013) Rol symptomatychnoi terapii antyoksydantnoho spriamuvannia v likuvanni khvorykh na rozsiianyi skleroz [The role of antioxidant symptomatic therapy in the treatment of patients with multiple sclerosis]. Mizhnarodnyi nevrolohichnyi zhurnal, 5, 81–87. [in Ukrainian].
Wu, H., Fu, S., Zhao, M., Lu, L., & Lu, Q. (2016). Dysregulation of Cell Death and Its Epigenetic Mechanisms in Systemic Lupus Erythematosus. Molecules, 22(1), 30. doi: 10.3390/molecules22010030.
Clancy, R. M., Markham, A. J., & Buyon, J. P. (2016). Endosomal Toll‐like receptors in clinically overt and silent autoimmunity. Immunological reviews, 269(1), 76–84. doi: 10.1111/imr.12383.
Rombouts, Y., Jónasdóttir, H. S., Ederveen, A. L. H., Reiding, K. R., Jansen, B. C., Freysdottir, J., & Wuhrer, M. (2016). Acute phase inflammation is characterized by rapid changes in plasma/peritoneal fluid N-glycosylation in mice. Glycoconjugate journal, 33(3), 457–70. doi: 10.1007/s10719-015-9648-9.
Blauth, K., Owens, G. P., & Bennett, J. L. (2015).The Ins and Outs of B Cells in Multiple Sclerosis. Front Immunol, 6, 565. doi: 10.3389/fimmu.2015.00565.
Biermann, M. H. C., Griffante, G., Podolska, M. J., Boeltz, S., Stürmer, J., Muñoz, L. E., et al. (2016). Sweet but dangerous – the role of immunoglobulin G glycosylation in autoimmunity and inflammation. Lupus, 25(8), 934–42. doi: 10.1177/0961203316640368.
Sjöwall, C., Zapf, J., von Löhneysen, S., Magorivska, I., Biermann, M., Janko, C., et al. (2015). Altered glycosylation of complexed native IgG molecules is associated with disease activity of systemic lupus erythematosus. Lupus, 24(6), 569–81. doi: 10.1177/0961203314558861.
Stümer, J., Biermann, M.H.C., Knopf, J., Magorivska, I., Kastbom, A., Svärd, A., et al. (2017). Altered glycan accessibility on native immunoglobulin G complexes in early rheumatoid arthritis and its changes during therapy. Clin Exp Immunol, 189(3), 372–382. doi: 10.1111/cei.12987.
Fickentscher, C., Magorivska, I., Janko, C., Biermann, M., Bilyy, R., Nalli, C., et al. (2015). The Pathogenicity of Anti- β 2GP1-IgG Autoantibodies Depends on Fc Glycosylation. J Immunol Res, 1–12. doi:10.1155/2015/638129.
Bournazos, S., DiLillo, D. J., & Ravetch, J. V. (2015). The role of Fc–FcγR interactions in IgG-mediated microbial neutralization. Journal of Experimental Medicine, 212(9), 1361–9. doi: 10.1084/jem.20151267.
Kaneko, Y., Cho, T., Sato, Y., Goto, K., Yamamoto, S., Goto, S., et al. (2018). Attenuated Macrophage Infiltration in Glomeruli of Aged Mice Resulting in Ameliorated Kidney Injury in Nephrotoxic Serum Nephritis. J Gerontol A Biol Sci Med Sci., 73(9), 1178–1186. doi: 10.1093/gerona/gly019.
Förger, F., & Østensen, M. (2010) Is IgG galactosylation the relevant factor for pregnancy-induced remission of rheumatoid arthritis? Arthritis Research & Therapy, 12, 108. doi: 10.1186/ar2919.
Quast, I., Peschke, B., & Lünemann, J. D. (2017). Regulation of antibody effector functions through IgG Fc N-glycosylation. Cellular and molecular life Sciences, 74(5), 837–847. doi: 10.1007/s00018-016-2366-z.
Schwedler, C., Häupl, T., Kalus, U., Blanchard, V., Burmester, G. R., Poddubnyy, D., & Hoppe, B. (2018). Hypogalactosylation of immunoglobulin G in rheumatoid arthritis: relationship to HLA-DRB1 shared epitope, anticitrullinated protein antibodies, rheumatoid factor, and correlation with inflammatory activity. Arthritis Res Ther., 20(1), 44. doi: 10.1186/s13075-018-1540-0.
Gajofatto, A., Nourbakhsh, B., Benedetti, M. D., & Waubant, E. (2018). Performance of 2010 McDonald criteria and 2016 MAGNIMS guidelines in the diagnosis of primary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry, 89(5), 550–552. doi: 10.1136/jnnp-2017-316911.
Raphael, I., Webb, J., Stuve, O., Haskins, W., & Forsthuber, T. (2015). Body fluid biomarkers in multiple sclerosis: how far we have come and how they could affect the clinic now and in the future. Expert review of clinical immunology, 11(1), 69–91. doi: 10.1586/1744666X.2015.991315.
Chen, S., Lu, C., Gu, H., Mehta, A., Li, J., Romano, P. B., et al. (2012). Aleuria Aurantia Lectin (AAL)-reactive immunoglobulin G rapidly appears in sera of animals following antigen exposure. PLoS One, 7(9), e44422. doi: 10.1371/journal.pone.0044422.
Downloads
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)
